Premium
The world‐wide incidence of Kaposi's sarcoma in the HIV / AIDS era
Author(s) -
Liu Z,
Fang Q,
Zuo J,
Minhas V,
Wood C,
Zhang T
Publication year - 2018
Publication title -
hiv medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.53
H-Index - 79
eISSN - 1468-1293
pISSN - 1464-2662
DOI - 10.1111/hiv.12584
Subject(s) - medicine , incidence (geometry) , context (archaeology) , kaposi's sarcoma , sarcoma , immunosuppression , human immunodeficiency virus (hiv) , demography , immunology , pathology , paleontology , physics , human herpesvirus , sociology , optics , biology
Objectives Kaposi's sarcoma ( KS ) is a multicentric angioproliferative cancer of endothelial origin typically occurring in the context of immunosuppression or immunodeficiency. Consequently, KS is one of the most common cancers in HIV ‐infected individuals and frequently occurs among transplant recipients. Nevertheless, its incidence in different populations is not well understood. Methods We searched online databases for publications on KS incidence. A random‐effect meta‐analysis was performed to combine the KS incidences and incidence rate ratios ( IRR s) for associated risk factors. Results Seventy‐six eligible studies representing 71 time periods were included. For HIV ‐infected people, the overall KS incidence was 481.54 per 100 000 person‐years with a 95% confidential interval ( CI ) of 342.36–677.32 per 100 000 person‐years. HIV ‐infected men who have sex with men ( MSM ) had the highest incidence of KS (1397.11 per 100 000 person‐years; 95% CI 870.55–2242.18 per 100 000 person‐years). The incidence of KS was significantly lower in female than in male individuals ( IRR 3.09; 95% CI 1.70–5.62). People receiving highly active antiretroviral therapy ( HAART ) had a lower incidence compared with people who had never received HAART ( IRR 6.57; 95% CI 1.91–24.69). The incidence of KS was 68.59 (95% CI 31.39–149.86) per 100 000 person‐years in transplant recipients, 52.94 (95% CI 39.90–70.20) per 100 000 person‐years in children with HIV infection, and 1.53 (95% CI 0.33–7.08) per 100 000 person‐years in the general population. Conclusions Globally, a relatively high incidence of KS was found among HIV ‐seropositive people and, in particular, in HIV ‐infected MSM . The introduction of HAART has largely prevented the development of KS , but it has not entirely removed the challenge of KS . In Africa, in particular, KS imposes a very heavy disease burden, which can mainly be attributed to the high prevalence of KS ‐associated herpesvirus and poor access to HAART .